Quinazolinone analogs as potential therapeutic agents

Current Medicinal Chemistry

Volumn 18, Issue 31, 2011, Pages 4786-4812

  Sharma, P C ^a   Kaur, G ^a   Pahwa, R ^a   Sharma, A ^a   Rajak, H ^b  

^a KURUKSHETRA UNIVERSITY   (India)

^b GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Heterocycles; Pharmacological significance; Quinazolinone

Indexed keywords

2 [(3,6 DIOXOPYRIDAZIN 4 YL)THIO] 3 BENZYL 4 OXO 6 IODO 3H QUINAZOLINE; 2 [2 HYDROXY 3 METHOXYPHENYL] 3 [HYDROXYL 3 METHOXYBENZYLAMINO] 1,2 DIHYDROQUINAZOLIN 4(3H) ONE; 2 PHENOXYMETHYL 3H QUINAZOLIN 4 ONE; 2(1H) QUINAZOLINONE (1H 1,3 QUINAZOLIN 2 ONE); 2,4(1H,3H) QUINAZOLINEDIONE (1H,3H 1,3 QUINAZOLINE 2,4 DIONE); 3 (3,4,5 TRIMETHOXYBENZYLIDENEAMINO) 6,8 DIBROMO 2 PHENYLQUINAZOLIN 4(3H) ONE; 3,4 DIHYDRO 1H,6H [1,4] OXAZINO [3,4 B] QUINAZOLIN 6 ONE; 4(3H) QUINAZOLINONE (3H 1,3 QUINAZOLIN 4 ONE); 6 CHLORO 2 STYRYL 3 (PYRIMIDIN 2 YL) 4(3H) QUINAZOLINONE; AMINOQUINAZOLINONE DERIVATIVE; AMPHOTERICIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CHOLINESTERASE INHIBITOR; COLCHICINE; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; FLUCONAZOLE; ITRACONAZOLE; N BENZOYL N' [2 (3 BENZYL 4 OXO6 IODO 3H QUINOZOLIN 2 YL)THIOACETYL]HYDRAZINE; N' [(3 BENZYL 4 OXO 6 IODO 3H QUINAZOLIN 2 YL) THIOACETYL] N 3 ETHYLTHIOSEMICARBAZIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NORFLOXACIN; QUINAZOLINE; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ANTIFUNGAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDIASIS; CARBON NUCLEAR MAGNETIC RESONANCE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHOLINESTERASE INHIBITION; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NEUTRON CAPTURE THERAPY; NONHUMAN; PENICILLIUM NOTATUM; POLYMERIZATION; PROTEUS MIRABILIS; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHI; SEIZURE; SHIGELLA FLEXNERI; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET SPECTROSCOPY;

ANTI-ALLERGIC AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINONES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 80054859208     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797535326     Document Type: Article

References (192)

1. Kostakis, I.K.; Elomri, A.; Seguin, E.; Iannelli, M.; Besson, T. Rapid synthesis of 2,3-disubstituted-quinazolin-4-ones enhanced by microwave assisted decomposition of formamide. Tetrahedron lett., 2007, 48, 6609-6613. (Pubitemid 47284260)
2. Nanda, A.K.; Ganguli, S.; Chakraborty, R. Antibacterial activity of some 3- (Arylideneamino)-2-phenylquinazolin-4(3H)-ones: Synthesis and preliminary QSAR studies. Molecules, 2007, 12, 2413-2426.
3. Potewar, T.M.; Ingale, S.A.; Srinivasan, K.V. Synthesis of tryptanthrin and deoxyvascinone by regioselective lithiation-intramolecular electrophillic reaction approach. ARKIVOC, 2008, xiv, 100-108.
4. You, J.; Ye, C.; Weng, Y.; Mo, X.; Wang, Y. Synthesis and anticoccidial activity of 4-(2-methoxyphenyl)-2-oxobutylquinazolinone derivatives. ARKIVOC, 2008, xvii, 1-11.
5. Mason, J.J. Synthetic studies of heterocyclic natural products. PhD Thesis, Karolinska Institute: Stockholm, Sweden, 2009.
6. Welch, W.M.; Ewing, F.E.; Huang, J.; Menniti, F.S.; Pagnozzi, M.J.; Kelly, K.; Seymour, P.A.; Guanowsky, V.; Guhan, S.; Guinn, M.R.; Critchett, D.; Lazzaro, J.; Ganong, A.H.; DeVries, K.M.; Staigers, T.L.; Chenard, B.L. Atropisomeric quinazolin-4-one derivatives are potent noncompetitive ć- amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists. Bioorg. Med. Chem. Lett.,2001, 11, 177-181. (Pubitemid 32101442)
7. Kashaw, KS.; Kashaw, V.; Mishra, P.; Jain, N.K. Design, synthesis and potential CNS activity of some novel 1-(4-substituted-phenyl)-3-(4-oxo-2- propyl-4H-quinazolin-3-yl)-urea. ARKIVOC, 2008, 15, 17-26.
8. Bansal. R.K. Heterocyclic chemistry: Synthesis, reactions and mechanisms. Wiley Eastern Ltd., 1990, pp. 375-377
9. Gursoy, A.; Unal, B.; Karali, N.; Otuk, G. Synthesis, characterization and primary antimicrobial activity evaluation of 3-Phenyl-6-methyl-4(3H)- quinazolinone-2-yl-mercaptoacetic acid arylidenehydrazides. Turk. J. Chem., 2005, 29, 233-245. (Pubitemid 40993194)
10. Sadeghian, T. Microwave irradiation promoted synthesis of some novel quinazolinone derivatives. M.S. Thesis, Shahid Beheshti University, January 1997.
11. El-Hashash, M.A.; El-Metwally, A.M.; Eissa, A.M.F.; El-Gohary, A.M.F. Synthesis and biological evaluation of some new 4(3H)-quinazolinone derivatives as non classical antifolate. http://ipac.kacst.edu.sa/edoc/ 2009/173266-1.pdf (Accessed July 24, 2010).
12. Deetz, M.J.; Malerich, J.P.; Beatty, A.M.; Smith, B.D. One step synthesis of 4(3H)-quinazolinones. Tetrahedron Lett., 2001, 42, 1851-1854.
13. Ighilahriz, K.; Boutemeur, B.; Chami, F.; Rabia, C.; Hamdi, M.; Hamdi, S.M. A microwave assisted and heteropolyacids-catalysed cyclocondensation reaction for the synthesis of 4(3H)-quinazolinones. Molecules, 2008, 13, 779-789.
14. Liu, G.; Yang, S.; Song, B.; Xue, W.; Hu, D.; Jin, L.; Lu, P. Microwave assisted synthesis of N-arylheterocyclic substituted-4-aminoquinazoline derivatives. Molecules, 2006, 11, 272-278. (Pubitemid 43684789)
15. Cancer from Wikipedia, the free encyclopedia. http://en.wikipedia.org/ wiki /cancer. (Accessed on February 24, 2010).
16. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev., 2004, 4, 253ć264.
17. Kim, Y.J.; Kim, A.E.; Chung, M.L.; Im, C. Cytotoxic activity and threedimensional quantitative structure activity relationship of 2-aryl-1,8- naphthyridin-4-ones. Korean J. Physiol. Pharmacol., 2009, 13, 511ć516.
18. Jantova, S.; Repicky, A.; Paulovicova, E.; Letasiova, S.; Cipak, L. Antiproliferative activity and apoptosis induced by 6-bromo-2-(morpholin-1- yl)-4-anilinoquinazoline on cells of leukemia lines. Exp. Oncol., 2008, 30(2), 139-142. (Pubitemid 351951391)
19. Cipak, L.; Repicky, A.; Jantova, S. Growth inhibition and apoptosis induced by 2-phenoxymethyl-3H-quinazolin-4-one in HL-60 leukemia cells. Exp. Oncol., 2007, 29(1), 13-17. (Pubitemid 46713473)
20. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sundersanam, S. The protein kinase complement of the human genome. Science., 2002, 298, 1912-1934. (Pubitemid 35425239)
21. Loge, C.; Testard, A.; Thiery, V.; Lozach, O.; Blairvacq, M.; Robert, M..J.; Meijer, L.; Besson, T. Novel 9-oxo-thiazolo[5,4-f]quinazoline-2- carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies. Eur. J. Med. Chem., 2008, 43, 1469-1477. (Pubitemid 351890437)
22. Nerker, A.G.; Saxena, A.K.; Ghone, S.A.; Thaker, A.K. In Silico screening, synthesis and in vitro evaluation of some quinazolinone and pyridine derivatives as dihydrofolate reductase inhibitors for anticancer activity. E J. Chem., 2009, 6(1), 97-102.
23. Orfi, L.; Kokosi, J.; Szasz, G.; Kovesdi, I.; Mak, M.; Teplan, I.; Keri, G. Heterocondensed quinazolones: Synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-lH,6H- [1,4]oxazino-[3,4-b] quinazolin-6- one derivatives. Bioorg. Med. Chem., 1996, 4(4), 547-551.
24. Khalil, A.A.; Hamide, S.G.A.; Al-Obaid, A.M.; El-Subbagh, H.I. Substituted quinazolines, Part 2. Synthesis and in vitro anticancer evaluation of new 2- substituted mercapto-3H-quinazoline analogs. Arch. Pharm. Pharm. Med. Chem., 2003, 2, 95-103. (Pubitemid 36547177)
25. Chakraborty, A.K.; Thilagavathi, R. Computer aided design of selective COX-2 inhibitors: Molecular docking of structurally diverse cyclooxygenase-2 inhibitors using FlexX#. Internet Electron. J. Mol Des., 2004, 3(11), 704-719.
26. Argyou, A.; Blanchard, J.S.; Wetting, M.W.; Aladeqbami, B. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struc. Mol. Biol., 2006, 13(5), 408-413. (Pubitemid 43881580)
27. Grasso, S.; Micalea, N.; Monforteb, A.N.; Monfortea, P.; Polimenia, S.; Zappala, M. Synthesis and in vitro antitumour activity evaluation of 1-aryl- 1H,3H-thiazolo[4,3-b]quinazolines. Eur. J. Med. Chem., 2000, 35, 1115-1119. (Pubitemid 32050018)
28. Tripathi, K.D. Essentials of Medical Pharmacology. 5th ed.; Jaypee Brothers; medical publishers (P) Ltd: New Delhi. 2004, pp. 767.
29. Jiang, J.B.; Hesson, D.P., Dusak, B.A.; Dexter, D.L.; Kang, G.J; Hamel, E. Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. J. Med. Chem., 1990, 33, 1721-1728. (Pubitemid 20180634)
30. Chinigo, GM.; Paige, M.; Grindrod, S.; Hamel, E.; Dakshanamurthy, S.; Chruszcz, M.; Minor, W.; Brown, M.L. Asymmetric synthesis of 2,3- dihydro-2-arylquinazolin-4-ones: Methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity. J. Med. Chem., 2008, 51(15), 4620-4631.
31. Hour, M.J.; Huang, L.J.; Kuo, S.C.; Xia, Y.; Bastow, K.; Nakanishi, Y.; Hamel, E.; Lee, K.H. 6-Alkylamino- and 2,3-dihydro-3'-methoxy-2-phenyl- 4-quinazolinenones and related compounds: Their synthesis, cytotoxicity and inhibition of tubulin polymerization. J. Med. Chem., 2000, 43, 4479-4487. (Pubitemid 32046872)
32. Xia, Y.; Yang, Z.Y.; Hour, M.J.; Kuo, S.C.; Xia, P.; Bastow, K.F.; Nakanishi, Y.; Nampoothiri, P.; Hackl, T.; Hamel, E.; Lee, K.H. Antitumour agents. Part 204: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg. Med. Chem. Lett., 2001, 11(9), 1193-1196. (Pubitemid 32406083)
33. Raffa, D.; Edler, M.C.; Daidone, G.; Maggio, B.; Merickech, M.; Plescia, S.; Schillaci, D.; Bai, R.; Hamel, E. Synthesis, cytotoxicity, and inhibitory effects on tubulin polymerization of a new 3-heterocyclo substituted 2- styrylquinazolinones. Eur. J. Med. Chem., 2004, 39, 299-304. (Pubitemid 38457024)
34. Soloway, A.H.; Tjarks, W.; Barnum, B.A.; Rong, F.G.; Barth, R.F.; Codogni, I.M.; Wilson, J.G. The chemistry of neutron capture therapy. Chem. Rev., 1998, 98, 1515-1562. (Pubitemid 128635962)
35. Tjarks, W.; Gabel, D. Boron containing thiouracil derivatives for neutron capture therapy of melanoma. J. Med. Chem.,1991, 34, 315-319.
36. Di Meo, C.; Panza, L.; Capitani, D.; Mannina, L.; Banzato, A.; Rondina, M.; Renier, D.; Rosato, A.; Crescenzi, V. Hyaluronan as carrier of carboranes for tumour targeting in boron neutron capture therapy. Biomacromolecules, 2007, 8(2), 552-559. (Pubitemid 46323272)
37. Yamato, Y.; Sadayori, N. Synthesis and biological properties of carboranyl aziridines bearing cascade polyols. Bioorg. Med. Chem. Lett., 1996, 6(1), 9-12. (Pubitemid 26024281)
38. Genady, A.R. Promising carboranyl quinazolines for boron neutron capture therapy: Synthesis, characterization, and in vitro toxicity evaluation. Eur. J. Med. Chem., 2009, 44, 409-416.
39. Al-Rashood, S.T.; Aboldahab, I.A.; Nagi, M.N.; Abouzeid, L.A.; Abdel- Aziz, A.A.M.; Hamide, S.G.; Youssef, K.M.; Al-Obaida, A.M.; El-Subbagh, H.I. Synthesis, dihydrofolate reductase inhibition, antitumour testing and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg. Med. Chem., 2006, 14(24), 8608-8621. (Pubitemid 44667527)
40. World Health Organisation (1999). Report on infectious diseases: Removing obstacles to healthy development. Geneva, Switzerland: World Health Organization. http://www.who.int/infectious-disease-report/index-rpt99.html (Accessed on July 24, 2010).
41. Sharma, P.C.; Jain, S. Synthesis and antibacterial activity of certain novel 1- cyclopropyl-6-flouro-1,4-dihydro-7-4-substituted-piperazin-1-yl-4- oxoquinolin-3-carboxylates. Acta Pharm. Sciencia, 2008, 50, 35-40.
42. Chawla, R.; Sahoo, U.; Arora, A.; Sharma, P.C.; Radhakrishnan, V. Microwave assisted synthesis of some novel 2-pyrazoline derivatives as possible antimicrobial agents. Acta Pol. Pharm. Drug Res., 2010, 67(1), 55-61.
43. Almeida, C.G.; Diniz, C.G.; Silva, V.L.; Saraiva, M.F.; Hyaric, M.L.; Almeida, M.V. Antibacterial activity of lipophillic flouroquinolone derivatives. Med. Chem., 2009, 5(5), 1-3.
44. Sharma, P.C.; Jain A.; Jain, S. Flouroquinoline antibacterials: A review on chemistry, microbiology and therapeutic prospects. Acta Pol. Pharm. Drug Res., 2009, 66(6), 587-604.
45. Chawla, R.; Arora, A.; Parmeswaran, M.K.; Sharma, P.C.; Michael, S.; Ravi, T.K. Synthesis of novel 1,3,4-oxadiazole derivatives as potential antimicrobial agents. Acta Pol. Pharm. Drug Res., 2010, 67(3), 247-253.
46. Sharma, P.C.; Jain, A.; Jain, S.; Pahwa, R.; Yar, M.S. Ciprofloxacin: Review on developments in synthetic, analytical and medicinal aspects. J. Enz. Inhib. Med. Chem., 2010, 25(4), 577-589.
47. Sharma, PC.; Jain, S. Synthesis and in vitro antibacterial activity of some novel N-nicotinyl-1-ethyl-6-flouro-1,4-dihyro-7-piperazin-1-yl-4- oxoquinoline-3-carboxylates. Acta Pol. Pharm. Drug Res., 2008, 65(5), 551-586.
48. Aakashdeep.; Jain, S.; Sharma, P.C.; Verma, P.; Kumar, M.; Dora, C.P. Design and biological evaluation of biphenyl-4-carboxylic acid hydrazidehydrazone for antimicrobial activity. Acta Pol. Pharm. Drug Res., 2010, 67(3), 255-259.
49. Sharma, P.C.; Jain, A.; Jain, S. In: Therapeutic Perspestives of flouroquinolone antibacterials: An update. In: Proceedings of 1st rashtreeya yuva vaigyanik sammelan, NIT, Kurukshetra, Nov. 28-30 2008; pp. 234-239.
50. Sharma, P.C.; Sharma, S.V.; Sharma, A.; Suresh, B. 3D-QSAR CoMFA study of some heteroarylpyrroles as possible anticandida agents. Indian J. Pharm. Sci., 2008, 70(2), 154-158. (Pubitemid 351920188)
51. Ramos, G.; Estrella, M.C.; Monzon, A.; Tudela, J.L. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother., 1999, 44, 283-286. (Pubitemid 29389293)
52. Sharma, P.C.; Sharma, S.V.; Shrishailappa, B.; Sharma, A.; Suresh, B. Microwave assisted efficient synthesis and anti-fungal evaluation of some NPhenyl- 3-(substituted phenyl) propenamides. Indian J. Pharm. Edu. Res., 2007, 41(2), 140-145.
53. Sharma, P.C.; Sharma, S.V.; Jain, S.; Singh, S.; Suresh, B. Synthesis of some new isoxazoline derivatives as possible anti-candida agents. Acta Pol. Pharm. Drug Res., 2009, 66(1), 101-104.
54. Kharb, R.; Sharma, P.C.; Yar, M.S. Pharmacological significance of triazole scaffold. J. Enz. Inhib. Med. Chem., 2011, 26(1), 1-21. doi: 10.3109/14756360903524304.
55. Jantova, S.; Stanvosky, S.; Spirkova, K. In vitro antibacterial activity of ten series of substituted quinazolines. Biologia Bratislava, 2004, 59(6), 741-752. (Pubitemid 40346268)
56. Singh, T.; Sharma, S.; Srivastava, V.; Kumar, A. Synthesis, insecticidal and antimicrobial activities of some heterocyclic derivatives of quinazolinone. Indian J. Chem., 2006, 45B, 2558-2565. (Pubitemid 44951873)
57. Algarswamy, V.; Murugesan, S.; Dhanabal, K.; Murugan, M.; Cercq, D.E. Anti HIV, antibacterial and antifungal activities of some novel 2-methyl-3- (substituted methylamino)-(3H)-quinazolin-4-ones. Indian J. Pharm. Sci., 2007, 69(2), 304-307. (Pubitemid 47026123)
58. El- Shareif, A.M.; Micky, J.A.A.; Sharaf, H.F. Synthesis and antimicrobial activity of newly fused quinazolinone derivatives. J. Taibah Univ. Sci., 2008, 1, 51-60.
59. Chandrika, M.P.; Yakaiah, T.; Narsaiah, B.; Sridhar, V.; Venugopal, G.; Rao, J.V.; Kumar, K.P.; Murthy, U.S.N.; Rao, A.R. Synthesis leading to novel 2,4,6-trisubstituted quinazoline derivatives, their antibacterial and cytotoxic activity against THP-1, HL-60 and A-375 cell lines. Indian J. Chem., 2009, 48B, 840-847.
60. Gudasi, K.B.; Havanur, V.C.; Patil, S.A, Patil, B.R. Antimicrobial study of newly synthesized lanthanide (III) complexes of 2-[2-hydroxy-3- methoxyphenyl]-3-[2-hydroxy-3-methoxybenzylamino]-1,2- dihydroquinazolin-4(3H)- one. Metal-Based Drugs, 2007, 2007:37348 doi: 10.1155/2007/37348. (Pubitemid 351441740)
61. Desai, R.; Desai, A.; Kishore, R. Niementowski reaction: Microwave induced and conventional synthesis of quinazolinones and 3-methyl-1H-5- pyrazolones and their antimicrobial activity. ARKIVOC, 2005, 8, 98-108. (Pubitemid 40757042)
62. Patel, B.B.; Patel, R.G.; Patel, M.P. Synthesis and studies of the biological activity of novel pyrimido fused acridine derivatives. J. Serb. Chem. Soc., 2006, 71(10), 1015-1023.
63. Khairy, A.M.; El-Bayouki, Aly, M.M, Mohamed, Y.A.; Basyouni, W.M.; Abbas, Y.S. Novel 4(3H)-quinazolinone containing biologically active thiazole, pyrazole, 1,3-dithiazole, pyridine, chromene, pyrazolopyrimidine and pyranochromene of Expected Biological Activity. World J. Chem., 2009, 4(2), 161-170.
64. Kohli, D.; Hashim, SR.; Sagar, V.; Sharma, M.; Singh, A.K. Synthesis and antibacterial activity of quinazolinone derivatives. Int. J. Pharm. Pharmaceut. Sci., 2009, 1(1), 163-169.
65. Mosaad, S.M.; Mohammed, K.I.; Ahmed, M.A.; Abdel-Hamide, S.G. New quinazoline related derivatives with antimicrobial activity: Part-1. Pak. J. Biol. Sci., 2004, 7(7), 1262-1268.
66. Panneerselvam, P.; Rather, B.A.; Reddy, D.R.S.; Kumar, N.R. Synthesis and anti-microbial screening of some schiff bases of 3-amino-6,8-dibromo-2- phenylquinazolin-4(3H)-ones. Eur. J. Med. Chem., 2009, 44, 2328-2333.
67. Pandey, S.K.; Singh, A.; Singh, A.; Nizzamudin. Antimicrobial studies of some novel quinazolinones fused with [1,2,4]-triazole, [1,2,4]-triazine and [1,2,4,5]-tetrazine rings. Eur. J. Med. Chem., 2009, 44, 1188-1197.
68. Fawzy, N.M.; Swelem, S.A.; Farid, M.A. Synthesis and antimicrobial activity of 3,4-dihydroquinazolinone, quinoxaline, benzoxazine, benzothiazine, pyran and pyrrolidinedione derivatives. Biotechnology, 2008, 7(1), 43-50.
69. Patel, N.B.; Patel, V.N. Synthesis and antimicrobial evaluation of new (4- oxo-thiazolidinyl)-quinazolin-4(3H)-ones of 2-[(2,6-dichlorophenyl)amino]- phenylacetic acid. Iran. J. Pharm. Res., 2007, 6(4), 251-258. (Pubitemid 351338513)
70. Singh, V.K.; Pandey, V.K. Synthesis, antibacterial and antifungal activity of some new pyrido quinazolones. Indian J. Chem., 2006, 45B, 2745-2748.
71. Jombo, G.T.A.; Denen, Akaa, P.; Alao, O.O.; Peters, E.J.; Dauda, M.A.; Okwari, E.E.; Akosu, T.J.; Etu, Kumana, E.A.; Yaakugh, J.B. Choices of drugs for self treatment of malaria among adult women in a Nigerian city: Implications for the success of the ongoing 'roll back' malaria programme. J. Microbiol. Antimicrob., 2010, 2(6), 57-63.
72. Zhu, S.; Hudson, T.H.; Kyle, D.E.; Lin, A.J. Synthesis and in vitro studies of novel pyrimidinyl peptidomimetics as potential antimalarial therapeutic agents. J. Med. Chem., 2002, 45(16), 3491.
73. Koepfli, J.B.; Mead, J.F.; Brockman, J.A. An alkaloid with high anti malarial activity from Dichroa febrifuga. J. Am. Chem. Soc., 1947, 69, 1837.
74. Koepfli, J.B.; Mead, J.F.; Brockman, J.A. Alkaloids of Dichroa febrifuga. I. Isolation and degradative studies. J. Am. Chem. Soc.,1949, 71, 1048-1054.
75. Chien, P.L; Cheng, C.C. Structural modifications of febrifugine: Some methylenedioxy analogs. J. Med. Chem., 1970, 13(5), 867-870.
76. Takeuchi, Y.; Koike, M.; Azuma, K.; Nishioka, H.; Abe, H.; Kim, S.H.; Wataya, Y.; Harayama, T. Synthesis and antimalarial activity of febrifugine derivatives. Chem. Pharm. Bull., 2001, 49(6), 721-725. (Pubitemid 32587119)
77. Mishra, D.N.; Sharma, P.C.; Jain, S. Chemotherapeutic agents targeting tuberculosis. Interdisciplinary Approach for Tuberculosis Control, S.R. Garg., A. Kumar and Y. Singh (Editors), CCS Haryana Agricultural University, Hisar, 2007, 70-77.
78. Tripathi, R.P.; Tewari, N.; Dwivedi, N.; Tiwari, V.K. Fighting tuberculosis: An old disease with new challenges. Med. Res. Rev., 2005, 25, 131(1-75)
79. World Health Organisation. Global Tuberculosis Control; WHO Report 2001;
80. World Health Organisation: Geneva, Switzerland; WHO/CDS/TB/2001.287.
81. World Health Organisation Tuberculosis Fact Sheet, No. 104, 2000; http://www.who.int/inf-fs/en/fact104.html.
82. Mooran, N. World Health Organisation issues another gloomy tuberculosis report, Nature Medicine, 1996, 2, 377.
83. Jr. Snider, D.E.; Raviglione, M.; Kochi, A. In: Tuberculosis: Pathogenesis and control; ed: BR. Bloom, Am. Soc. Microbiology, Washington, DC, 1994, pp. 2-11.
84. Dye, C.; Scheele, S.; Dolin, P,; Pathania, V.; Raviglione, M.C. Global burden of tuberculosis: E stimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. J. Am. Med Assoc., 1999, 282, 677-686.
85. Farmer, P.; Bayona, J.; Beccera, M.; Furin, J.; Henry, C.; Hiarr, H.; Kim, J.Y.; Mimic, C.; Nardell, E.; Shin S. The dilemma of MDR TB in global era. Int. J. Tuberc. Lung Dis. 1998, 2, 869-876.
86. Singh, M.M.; Bano, T.; Pagare, D.; Sharma, N.; Devi, R.; Mehra, M. Knowledge and attitude towards tuberculosis in a slum community of Delhi. J. Commun. Dis., 2002, 34(3), 203-214. (Pubitemid 38698636)
87. Al-deeb, A.O.; Alafeefy, A.M. Synthesis of some new 3H-quinazolin-4-one derivatives as potential antitubercular agents. World Applied Sciences Journal, 2008, 5(1), 94-99.
88. Yew, W.W.; Leung, C.C. Antituberculosis drugs and hepatotoxicity. Respirology, 2003, 11, 699-707. (Pubitemid 44581433)
89. Biava, M.; Porretta, A.; Manetti, F. A class of antimycobacterial compounds based on the pyrrole ring as a scaffold. Mini. Rev. Med. Chem., 2007, 7, 65-78. (Pubitemid 46062375)
90. Guersoy, A.; Illhan, N. Synthesis and antimicrobial evaluation of new quinazolinone derivatives. Il Farmaco, 1995, 50, 559-562.
91. Pandeya, S.N.; Sriram, D.; Nath, G.; Clerke, E.De. Synthesis, antibacterial, antifungal and anti HIV evaluation of Schiff and mannich bases of isatin derivatives with 3-amino-2-methylmercaptoquinazolin-4(3H)-one. Pharm. Acta. Helv.,1999, 74, 11-17. (Pubitemid 30035398)
92. Grover, G.; Kini, S.G. Synthesis and evaluation of new quinazolone derivatives of nalidixic acid as potential antibacterial and antifungal agents. Eur. J. Med. Chem., 2006, 41, 256-262.
93. Kunes, J.; Bazant, J.; Pour, M.; Waisser, K.; Slosarek, M.; Janota, J. Quinazoline derivatives with antitubercular activity. Il Farmaco, 2000, 55, 725-729. (Pubitemid 32037105)
94. Waisser, W.; Bures, O.; Holy, P.; Kunes, J.; Oswald, R.; Jiraskova, L.; Pour, M.; Klimesova, V.; Palat, K.; Kaustova, J.; Danse, H.M.; Mollmann, U. Antimycobacterial 3-aryl-2H-1,3-benzoxazine-2,4(3H)-diones. Pharmazie, 2003, 58(2), 83-94. (Pubitemid 36267907)
95. Waisser, K.; Perina, M.; Kunes, J.; Klimesova, V.; Kaustova, J. 3-Benzyl- 2H-1,3-benzoxazine- 2,4(3H)-diones, a new group of antimycobacterial compounds against potentially pathogenic strains. Il Farmaco, 2003, 58, 1137-1149. (Pubitemid 37323933)
96. Waisser, K.; Matyk, J.; Divisova, H.; Husakova, P.; Kunes, J.; Klimesova, V.; Palat, K.; Kaustova, J. The oriented development of antituberculotics (Part II): Halogenated 3-(4-Alkylphenyl)-1,3- benzoxazine-2,4-(3H)-diones. Arch. Pharm. (weinheim), 2007, 340(5), 264-267. (Pubitemid 46959729)
97. Sharma, P.C.; Sharma, O.P.; Vasudeva, N.; Mishra, D.N.; Singh, S.K. Anti- HIV substances of natural origin-An Updated Account. Natural Product Radiance, 2006, 5(1), 70-77.
98. Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220, 868-71. (Pubitemid 13080157)
99. Gallo, R.C.; Salahuddin, S.Z.; Popovic, M.; Shearer, G.M.; Kaplan, M.; Haynes, B.F. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224, 500-503. (Pubitemid 14134741)
100. Kakkar, S.; Mohanraj, K.; Aakashdeep.; Sharma, P.C. Simple and rapid RPHPLC method for chromatographic purity of anti-retroviral drug lamivudine. Lat. Am. J. Pharm., 2010, 29(7), 1075-1081.
101. De Clercq, E. Non- nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present and future. Chem. Biodiversity, 2004, 1, 44-64.
102. Ellis, D.; Kuhen, K.L.; Anaclerio, B.; Wu, B.; Wolff, K.; Yin, H.; Bursulaya, B.; Caldwell, J.; Karenewsky, D.; He, Y. Design, synthesis and biological evaluations of novel quinolones as HIV-1 non- nucleoside reverse trancriptase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 4246-4251.
103. Singla, S.; Kumar, H.; Sharma, P.C. In: Bioinformatics in pharma research. In bioinformatics computing. Narosa publishing house, 2007, New Delhi, India, pp. 131-138.
104. Potter, S.J.; Chew. C.B.; Steain, M.; Dwyer, D.E.; Saksena, N.K. Obstacles to successful antiretroviral treatment of HIV-1 infection: Problems & perspectives. Indian J. Med. Res., 2004, 119, 217-237. (Pubitemid 39076952)
105. Yuvraj, G.; Meena, A.; Dillibabu.; Kumar, G.S.; Arvind, M.; Kumar, N.R. Synthesis, anti-viral and cytotoxic studies of some 2-phenyl-3-substituted quinazolin-4-(3H)-ones. Int. J. Pharm. Res., 2009, 1(3), 141-145.
106. Gao, X.; Cai, X.; Yan, K.; Song, B.; Gao, L.; Chen, Z. Synthesis and antiviral bioactivities of 2-aryl- or 2-methyl-3-(substituted-benzalamino)- 4(3H)-quinazolinone derivatives. Molecules, 2007, 12, 2621-2642.
107. Malaskwa, B. New anticonvulsant agents. Curr. Topics in Med. Chem., 2005, 5, 69-85.
108. Duncan, J.S. The promise of new antiepileptic drugs. Br. J. Clin. Pharmacol., 2002, 53, 123-131. (Pubitemid 34264266)
109. Archana.; Srivastava, V.K.; Kumar, A. Synthesis of some newer derivatives of substituted quinazolinonyl-2-oxo/thiobarbituric acid as potent anticonvulsant agents. Bioorg. Med. Chem., 2004, 12, 1257-1264. (Pubitemid 38251316)
110. Srivastava, A.V.K.; Kumar, A. Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4(3H)-ones as potential anticonvulsant agents. Eur. J. Med. Chem., 2002, 37, 873-882. (Pubitemid 35356423)
111. Helby, A.G.; Hameda, M.; Wahab, A. Design and synthesis of some new derivatives of 3H-quinazolin-4-one with promising anticonvulsant activity. Acta Pharm., 2003, 53, 127-138. (Pubitemid 36850884)
112. Wolfe, J.F.; Rathman, T.L.; Sleevi, M.C.; Campbell, J.A.; Greenwood, T.D. Synthesis and anticonvulsant activity of some new 2-substituted-3-aryl-(3H)- quinazolinones. J. Med. Chem., 1990, 33(1),161-166. (Pubitemid 20038187)
113. White, D.C.; Greenwood, T.D.; Downey, A.L.; Bloomquist, A.R.; Wolfe, J.F. Synthesis and anticonvulsant evaluation of some new 2-substituted-3- arylpyrido[2,3-d]pyrimidinones. Bioorg. Med. Chem., 2004, 12, 5711-5717. (Pubitemid 39304068)
114. Angelo,. M.; Plattner, F.; Irvine, E.E.; Giese, K.P. Improved reversal learning altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur. J. Neurosci., 2003, 18(2), 423-431. (Pubitemid 36999943)
115. Chen, P.C.; Chen, J.C. Enhanced CDK5 activity and p35 translocation in the venral striatum of acute and chronic methamphetamine-treated rats. Neuropsychopharmacol., 2005, 30(3), 538-549.
116. Lindskog, M.; Svenningsson, P.; Pozzi, L.; Kim, Y.; Fienberg, A.A.; Bibb, JA.; Freholm, B.B.; Greengard, P.; Fisone, G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature, 2002, 418(6901), 774-778.
117. Rzasa, R.M.; Kaller, M.R.; Liu, G.; Magal, E.; Nguyen, T.T.; ,Osslund, T.D.; Powers, D.; Santora, V.J.; Viswanadhan, V.N.; Wang, HL.; Xiong, X.; Zhonga, W.; Normana, M.H. Structure-activity relationships of 3,4-dihydro- 1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorg. Med. Chem., 2007, 15, 6574-6595. (Pubitemid 47302311)
118. Tiwari, S.S.; Satsangi R.K.; Agarwal, R. Synthesis and CNS activity of some 2-Aryl/Alkyl-3-[N-phenyl-N-(dihydroxy-phenyl-methyl)-amino]-6,8- disubstituted quinazolin-4(3H)-ones. Curr. Sci., 1979, 48, 568-571.
119. Omar-Al, M.A.; Azab-El Adel, S.; Obeid-El, H.A.; Hamide, S.G. Synthesis of some new 4-(3H)-quinazoline analogs as potential antioxidant agents. J. Saudi Chem. Soc., 2006, 10, 113-130.
120. Sati, N.; Kumar, S.; Rawat, M.S.M. Synthesis, structure activity relationship studies and pharmacological evaluation of 2-phenyl-3-(substituted phenyl)- 3H-quinazolin-4-ones as serotonin 5-HT2 antagonist. Indian J. Pharm. Sci., 2009, 71(5), 572-575.
121. Jatav, V.; Mishra, P.; Kashaw, S.; Stables, J.P. CNS depressant and anticonvulsant activities of some novel 3-[5-substituted-1,3,4-thiadiazole-2- yl]-2-styrylquinazoline-4(3H)-ones. Eur. J. Med. Chem., 2008, 43, 1945-1954.
122. Giacobini, E; In: Cognitive Enhancing Drugs; J.J. Buccafusco (Ed.), Birkhauser Verlag, Basel, Boston, Berlin, 2004, pp. 11-36.
123. Park, C.H.; Kim, S.H.; Choi, W.; Lee, Y.L.; Kim, J..S.; Kang, S.S.; Suh, Y.H. Novel anticholinesterase and antiamnesic activities of dihydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med., 1996, 62(5), 405-409. (Pubitemid 26370329)
124. Decker, M. Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. Eur. J. Med. Chem., 2005, 40, 305-313. (Pubitemid 40255773)
125. El-Gazzar, B.A.; Hafez, H.N.; Abbas, H.A.S. S- and C-nucleoside quinazoline as new nucleoside analogs with potential analgesic and antiinflammatory activity. Eur. J. Med. Chem., 2009, 44, 4249-4258.
126. Mollereau, C.; Parmentier, M.; Mailleux, P.; Butour, J.L.; Moisand, C.; Chalon, P.; Caput, D.; Vassart, G.; Meunier, J.C. ORL-1, a novel member of the opoid receptor family: Cloning, functional expression and localization. FEBS Lett., 1994, 341(1), 33-38.
127. Meunier, J.C.; Mollereau, C.; Toll, L.; Suaudeau, C.; Moisand, C.; Alvinerie, P.; Butour, J.L.; Guillemot, J.C.; Ferrara, P.; Monsarrat, B.; Mazarguil, H.; Vassart, G.; Parmentier, M.; Costentin, J. Isolation and structure of endogenous agonist of opoid receptor like ORL-1 receptor. Nature, 1995, 377, 532-535.
128. Ueda, H.; Yamaguchi, T.; Tokuyama, S.; Inoue, M.; Nishi, M.; Takeshima, H. Partial loss of tolerance liability to morphine analgesia in mice lacking nociceptin receptor gene. Neurosci. Lett., 1997, 237(3), 136-138. (Pubitemid 28004975)
129. Mogil, J.S.; Grisel, JE.; Reinscheid, R.K.; Civelli, O.; Belknap, J.K.; Grandy, D.K. Orphanin FQ is a functional anti opoid peptide. Neuroscience, 1996, 75(2), 333-337. (Pubitemid 26361325)
130. Manabe, T.; Noda, Y.; Mamiya, T.; Katagiri, H.; Houtani, T.; Nishi, M.; Noda, T.; Takahashi, T.; Sugimoto, T.; Nabeshima, T.; Takeshima, H. Facilitation of long term potentiation and memory in mice lacking nociceptin receptors. Nature, 1998, 394(6702), 577-581. (Pubitemid 28366832)
131. Florin, S.; Suaudeau, C.; Meunier, J.C.; Costentin, J. Nociceptin stimulates locomotion and exploratory behavior in mice. Eur. J. Pharmacol., 1996, 317(1), 9-13. (Pubitemid 26427007)
132. Okano, M.; Mito, J.; Maruyama, Y.; Masuda H.; Niwa, T.; Nakagawa, S.I.; Nakamura, Y.; Matsuura, A. Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists. Bioorg. Med. Chem., 2009, 17, 119-132.
133. Jankovic, J.J. Parkinson's disease: Clinical features and diagonosis. Neurol. Neurosurg. Psychiatry, 2008, 79, 368-376.
134. Suzuki, F.; Kuroda, T.; Nakasato, Y.; Manabe, H.; Ohmori, K.; Kitamura, S.; Ichikawa, S.; Ohno, T. New bronchodilators.1.1,5-substituted-1Himidazo[ 4,5-c]quinazolin-4(5H)-ones. J. Med. Chem., 1992, 35, 4045-4053.
135. Takase, Y.; Saeki, T.; Fujimoto, M.; Saito, I. Cyclic GMP phosphodiesterase inhibitors.1. The discovery of a novel potent inhibitor, 4-((3,4- methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline. J. Med. Chem., 1993, 36(24), 3765-3770. (Pubitemid 24006704)
136. Laddha, S.S.; Wadodkar, S.G.; Mehgal, S.K. cAMP dependent phosphodiesterase inhibition and SAR studies on novel 6,8-disubstituted-2- phenyl-3-(substituted benzothiazo-2-yl)-4(3H)-quinazolinone. Med. Chem. Res., 2009, 18(4), 268-276.
137. Takase, Y.; Saeki, T.; Watanabe, N.; Adachi, N.; Souda, S.; Saito, I. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J. Med. Chem., 1994, 37(13), 2106-2111. (Pubitemid 24233624)
138. Pandey, V.K.; Pathak, L.P.; Mishra, S.K. Synthesis and characterization of isoquinolinyl quinazolines and a study of their antiviral and antifungal activities. Indian J. Chem., 2005, 44B, 1940-1943. (Pubitemid 41503323)
139. Bojarski, A.; Kowalski, P.; Kovalska, B.; Duszyn, S.S.; Charakchieva, M.; Tatarczy, E.; Odzi, A.K.; Chojnacka-Wojcik, E. Synthesis and pharmacological evaluation of new arylpiperazines 3-{4-[4-(3- chlorophenyl)-1-piperazinyl]butyl} -quinazolidin-4-one - a dual serotonin 5- HT1A/5-HT2A receptor ligand with an anxiolytic like activity. Biorg. Med. Chem., 2002, 10(12), 3817-3827. (Pubitemid 36164682)
140. Kumar, S.; Kaur, H.; Singh, I.; Sharma, M.; Vishwakarma, P.; Saxena, K.K.; Kumar, A. Synthesis, characterization and biological activity of various substituted quinazolinone derivatives containing dopamine moiety. World J. Chem., 2009, 4(2), 195-200.
141. Hebb, A.L.; Robertson, H.A. Role of phosphodiesterase in neurological and psychiatric disease. Curr. Opin. Pharmacol., 2007, 7(1), 86-92. (Pubitemid 46242039)
142. Houslay, M.D.; Schafer, P.; Zhang, K.Y. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discovery Today, 2005, 10, 1503-1519. (Pubitemid 41527193)
143. Houslay M.D., Baillie, G.S., Maurice, D.H. cAMP specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ. Res., 2007, 100(7), 950-966. (Pubitemid 46598920)
144. Laddha, S.S.; Bhatnagar, S.P. A new therapeutic approach in Parkinson's disease: Some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. Bioorg. Med. Chem., 2009, 17, 6796-6802.
145. Saxena, A.K.; Saxena, M. Developments in antihistaminics (H1), In: Progress in Drug Research, Ernst Jucker, Basel, 1992, pp. 35-126.
146. Garrison, J.C. Histamine, Bradykinine, 5-Hydroxytryptamine and their antagonists, in: Gilman, A.G.; Rall, T.E.; Nies, A.S.; Taylor, P. (Eds.), The Pharmacological Basis of Therapeutics, 8th ed., Pergamon Press, New York, 1990, pp. 575.
147. Green, J.P.; Weinstein, H. In: Psychopharmacology: A Generation of Progress, Raven Press, New York, 1978, pp. 319.
148. Naruto, S.; Motoc, I.; Marshall, G.R. Computer-assisted analysis of bioactivity. I. Active conformation of histamine H1 receptor antagonists. Eur. J. Med. Chem., 1985, 20, 529-534.
149. Diurno, M.V.; Mazzoni, O.; Pescopo, E.; Calignano, A.; Giordano, F.; Bolognese, A. Synthesis and antihistaminic activity of some thiazolindin-4- ones. J. Med. Chem., 1992, 35(15), 2910-2912.
150. Simons, F.E.; Simons, K.J. Drug therapy: The pharmacology and use of H1- receptor antagonist drugs. N. Engl. J. Med., 1994, 330, 1663-1670.
151. Simons, K.J.; Benedetti, M.S.; Simons, F.E.R.,; Gillard, M.; Baltes, E. Relevance of H1 receptor occupancy to H1 antihistamine dosing in children. J. Allergy Clin. Immunol., 2007, 119(6), 1551-1554. (Pubitemid 46855868)
152. Chairungsrilerd, N.; Furukawa, K.; Ohta, T.; Nozoe, S.; Ohizumi, Y. Pharmacological properties of ć-mangostatin, a novel histamine H1 receptor antagonist. Eur. J. Pharmacol.,1996, 314(3), 351-356. (Pubitemid 26382440)
153. Rao, A.R.; Reddy, V.M. Synthesis of N- heteryl-ć-[(2- alkoxyethyl)oxy]/ć[[2-N,N-dialkylamino) ethyl]oxy]acetamides as possible H1- antihistaminics. Pharmazie, 1992, 47, 794-796.
154. Buyuktimkin, S.; Buyuktimkin, N.; Ozdemir, O.; Rollas, S. Quinazolinones,13. Comm. Synthesis of 3-[2-(2,3-dihydro-5-phenyl-4- substituted-3H-1,2,4-triazole-3-thione-2-yl)-acetylamino]-2-methyl-4(3H)- quinazolinones and their pharmacological activities. Arch. Pharm., 1989, 322, 49-51. (Pubitemid 19033310)
155. Raju, M.B.; Singh, S.D.; Rao, R.R.; Rajan, K.S. New antihistaminic agents: Synthesis and evaluation of H1 antihistaminic actions 3-[(N,N-dialkylamino)- alkyl]-1,2,3,4-tetrahydro-(1H)-thioquinazolin-4(3H)-ones and their oxo analogues. Indian J. Pharm. Sci., 2007, 69(6), 853-856.
156. Alagarsamy, V.; Rupeshkumar, M.; Kavitha, K.; Meena, S.; Shankar, D.; Siddiqui, A.A.; Rajesh, R. Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin- 5-ones as new class of H1-antihistaminic agents. Eur. J. Med. Chem., 2008, 43, 2331-2337.
157. Shishoo, C.J.; Shirsath, V.S.; Rathod, I.S.; Bhrambhat, S.B.; Pathak, U.S.; Jain, K.S.Synthesis and QSAR of some 3-amino-2-(substituted)- aminomethyl-5,6-disubstituted thieno[2,3-d]-pyrimidin-4(3H)-ones as novel H1- receptor antagonists. Drug Design Discovery, 1997, 15, 105-115. (Pubitemid 27429643)
158. Shishoo, C.J.; Shirsath, V.S.; Rathod, I.S.; Yande, V.D. Design, synthesis and antihistaminic (H1) activity of some condensed 3-aminopyrimidin- 4(3H)-ones. Eur. J. Med. Chem., 2000, 35, 351ć358.
159. Alagarswamy, V.; Prabhakaran, L.; Murugan, R.D.; Gurumurth, G.; Bindu, P.; Arunkumar, N.; Bothiraja, C. Synthesis and antihistaminic activity of some novel 2-mercapto-3-(substituted methylamino)-quinazolin-4(3H)-ones. Acta Pharm. Turcica, 2000, XLII(1), 33-38. (Pubitemid 30438580)
160. Kumar, V.; Sharma, A.; Sharma P.C. Synthesis of some novel 2,5- disubstituted thiazolidinones from a long chain fatty acid as possible antiinflammatory and hydrogen peroxide scavenging agents. J. Enz. Inhib. Med. Chem., 2011, 26(2), 198-203. doi 10.3109/14756366.2010.489897.
161. Verma, A.; Saraf, S.K. 4-Thiazolidinone- A biologically active scaffold. Eur. J. Med. Chem., 2008, 43, 897-905.
162. Hickenbottom, S.L.; Grotta, J. Neuroprotective therapy. Semin. Neurol., 1998, 18, 485-492. (Pubitemid 29058860)
163. Rajak, H.; Kharya, M.D.; Mishra, P. Synthesis of some novel oxadiazole and oxadiazole analogues for their anti inflammatory activity. Yaku Zasshi (J. Pharm. Soc. Japan), 2007, 127(10), 1757-1764. (Pubitemid 47511082)
164. Rajak, H.; Verasamy, R.; Singour, P.; Kharya, M.D.; Mishra, P. Design, synthesis and pharmacological evaluation of some novel oxadiazole and oxadiazoline analogues as anti- inflammatory agents J. Enz. Inhib. Med. Chem., 2010, 25(4), 492-501.
165. Sharma, P.C.; Yadav, S.; Pahwa, R.; Kaushik, D.; Jain, S. Synthesis and evaluation of novel prodrugs of naproxen. Med. Chem. Res. 2011, 20(5), 648-655. doi 10.1007/s00044-010-9364-8.
166. Aakashdeep.; Jain, S.; Sharma, P.C. Synthesis and antiinflammatory activity of some novel biphenyl-4-carboxylic acid 5-(arylidene)-2-(aryl)-4- oxothiazolidin-3-yl amides. Acta Pol. Pharm. Drug Res., 2010, 67(1), 63-67.
167. Saravanam, J.; Mohan, S.; Manjunatha, K.S. Synthesis and antiinflammatory activity of some 6-bromo-2,3-disubstituted-4(3H)- quinazolinones. Indian J. Heterocyl. Chem., 1998, 8, 55-58. (Pubitemid 128540662)
168. Goel, B.; Ram, T.; Tyagi, R.; Bansal, E.; Kumar, A.; Mukerjee, D.; Sinha, J.N. 2-substituted-3-(4-bromo-2-carboxyphenyl)-5-methyl-4-thiazolidinones as potential anti inflammatory agents. Eur. J. Med. Chem., 1999, 34(3), 265-269.
169. Kumar, A.; Sharma, S.; Archana.; Bajaj, K.; Sharma, S.; Panwar, H.; Singh, T.; Srivastava, V.K. Some new 2,3,6-trisubstituted quinazolinones as potent anti inflammatory, analgesic and COX-II inhibitors. Bioorg. Med. Chem., 2003, 11, 5293-5299. (Pubitemid 37353016)
170. Kevin, C.; Nikolaus, R. The evolution of gene regulation by transcription factors and micro RNAs. Nat. Rev. Genet., 2007, 8(2), 93-103.
171. Giri, R.S.; Thaker, H.M.; Giordano, T.; Williams, J.; Rogers, D.; Sudersanam, V.; Vasu, K.K. Design, synthesis and characterization of novel 2-(2,4-disubstituted-thiazole-5-yl)-3-aryl-3H-quinazoline-4-one derivatives as inhibitors of NF-kB and AP-1 mediated transcription activation and as potential anti-inflammatory agents. Eur. J. Med. Chem., 2009, 44, 2184-2189.
172. Kumar, A.; Rajput, C.S. Synthesis and anti inflammatory activity of newer quinazolin-4-ones. Eur. J. Med. Chem., 2009; 44: 83-90.
173. Hawash, A.M.; Badawey, A.M.; Ashmawey, I.M. Nonsteroidal anti inflammatory agents-part 2 antiinflammatory, analgesic and antipyretic activity of some substituted 3-pyrazolin-5-ones and 1,2,4,5,6,7-3Hhexahydroindazol- 3-ones. Eur. J. Med. Chem., 2006, 41, 155-165.
174. Alagarsamy, V.; Solomon, V.R.; Dhanabal, K. Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted-3H-quinazolin- 4-one as analgesic, anti-inflammatory agents. Bioorg. Med. Chem., 2007, 15, 235-241. (Pubitemid 44738581)
175. Kumar, A.; Rajput, C.S.; Bhati, S.K. Synthesis of 3-[4-(p-chlorophenyl)- thiazol-2-yl]-2-[(substituted azetidinone/thiazolidinone)-aminomethyl]-6- bromoquinazolin-4-ones as anti-inflammatory agent. Bioorg. Med. Chem., 2007, 15, 3089-3096. (Pubitemid 46400456)
176. Mohamed, M.S.; Kamel, M.M.; Kassem, E.M.M.; Abotaleb, N.; Nofel, S.M.; Ahmed, M.F. Novel 3-(p-substituted phenyl)-6-bromo-4(3H)-quinazolinone derivatives of promising anti-inflammatory and analgesic properties. Acta Pol. Pharm.Drug Res., 2009, 66(5), 487-500.
177. Habib, N.S.; Ismail, K.A.; El-Tombary, A.A.; Abd El-Aziem, T. Antilipidemic agents, Part IV: Synthesis and antilipidemic testing of some heterocyclic derivatives of hexadecyl and cyclohexyl hemisuccinate esters. Pharmazie, 2000, 55, 495-499. (Pubitemid 30471430)
178. Fuster, V.; Alexander, P.W.; O Rourke, R.A.; Roberts, R.; King SB.; Wellens, H.J. Atherogenesis and its determinants. In Hurst's the heart: Mc Graw-Hill, 10th ed.; New York, 2001; Vol. 3, pp. 1065.
179. Kurogi, Y.; Inoue, Y.; Tsutsumi, K.; Nakamura, S.; Nagao, K.; Yoshitsugu, H.; Tsuda, Y. Synthesis and hypolipidemic activities of novel 2-(4- [(diethoxyphosphoryl) methyl]phenyl) quinazolines and 4(3H)- quinazolinones. J. Med. Chem. 1996 39 1433-1437.
180. Gosain, S.; Ircchiaya, R.; Sharma, P.C.; Thareja, S.; Kalra, A.; Aakashdeep.; Bhardwaj, T.R. Hypolipidemic effect of ethanolic extract from the leaves of Hibiscus Sabdariffa L. in hyperlipidemic rats. Acta Pol. Pharm. Drug Res., 2010, 67(2), 179-184.
181. Krentz, AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes. Metab., 2003, 5, 19-27.
182. Refaie, FM.; Esmat, AY.; Gawad, S.; Ibrahim, A.M.; Mohamed, M.A. The antihyperlipidemic activities of 4(3H)-quinazolinone and two halogenated derivatives in rats. Lipids in health and disease, 2005, 4(22), 1-11.
183. Algarswamy, V.; Pathak, U.S. Synthesis and antihypertensive activity of novel 3-benzyl-2-substituted-3H-[1,2,4] triazolo [5,1-b]quinazolin-9-ones. Bioorg. Med. Chem., 2007, 15, 3457-3462. (Pubitemid 46529260)
184. Pandey, V.K.; Mukesh.; Kumar, A.; Trivedi, N. An investigation leading to preparation of tetrahydro-quinazoline derivatives involving ureidoalkylation and ć-amidoalkylation reactions. Indian J. Chem., 2008, 47B, 1910-1914.
185. Ram Ji, V.; Farhanullah; Tripathi, B.K.; Srivastava, A.K. Synthesis and antihyperglycemic activity of suitably functionalized 3H-quinazolin-4-ones. Bioorg. Med. Chem., 2003, 11, 2439-2444. (Pubitemid 36539380)
186. Bishnoi, A.; Awasthi, R.; Pandey, V.K.; Tiwari, A.K, Awasthi NK., Srivastava K, Singh S. Drug design based on the principle of conjunction: Synthesis, characterization and antihyperglycemic activity study of 3- [2- (3- aroyl- 2,4- diphenyl- 3 , 4- dihydro- 2h [1, 3] oxazino [5, 6-h] quinolin- 6- yl) ethyl] 2-phenyl- quinazolin- 4(3h)- ones. Int. J. Drug Disc., 2009, 1(2), 52-55.
187. Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. 11th ed.; John H Block, John M. Beale. Lippincott Williams and Wilkins. pp. 540.
188. Liu, J.F.; Jaekyoo, L.; Dalton, A.M.; Bi, G.; Yu, L.; Baldino, C.M.; McElory, C.; Brown, M. Microwave assisted one pot synthesis of 2,3-disubstituted 3Hquinazolin- 4-ones. Tetrahedron Lett., 2005, 46, 1241-1244.
189. Kar, Ashutosh.; Medicinal Chemistry, 2nd ed.; New Age International Publishers, 2005, pp. 89.
190. Li, F.; Feng, Y.; Meng, Q.; Li, W.; Li, Z.; Wang, Q.; Tao, F. An efficient construction of quinazolin-4(3H)-ones under microwave irradiation. ARKIVOC, 2007, 1, 40-50.
191. Sriram, D.; Yogeeswari, P. Medicinal Chemistry., First impression, 2007; Dorling Kindersley (India) Pvt. Ltd., 2007, pp. 192 and 410-411.
192. Baez, M.A.; Garg, D.C.; Jallad, N.S.; Weidler D.J. Antihypertensive effect of doxazosin in hypertensive patients: C omparison with atenolol. Br. J. Clin. Pharmac., 1986, 21, 63S-67S. (Pubitemid 17170742)